ArticleBMC microbiology2026
High burden of bla
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveKlebsiella pneumoniae, a major nosocomial pathogen, is increasingly associated with multidrug resistance and carbapenem production, posing a significant therapeutic challenge on a global scale. The study aimed to determine the distribution, antimicrobial susceptibility pattern, and molecular identification of bla
methodsBetween January and June 2024, a hospital-based cross-sectional study was carried out at Kirtipur Hospital in Nepal. Standard microbiological protocols were adopted for the processing of 5002 clinical samples. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion method following CLSI guidelines. The modified carbapenem inactivation method (mCIM) and the EDTA-modified carbapenem inactivation method (eCIM) were used to confirm carbapenemase production phenotypically, and the polymerase chain reaction (PCR) was used to detect the bla
resultsOf the total samples, 18.3% (917) showed bacterial growth, with K. pneumoniae accounting for 7.6% (n = 70) of isolates, predominantly from wound/pus (35.7%), urine (32.8%), and blood (17.1%) specimens. High resistance was observed against imipenem (68.6%), ceftazidime (64.3%), and ceftriaxone (62.9%), whereas tigecycline and doxycycline remained the most effective ones. Twelve (30.8%) of the 39 carbapenem-resistant isolates were determined to be carbapenemases producers, all harboring bla
conclusionThe dominance of KPC-mediated resistance among the hospitalized patients, underscores the need for rigorous infection control, ongoing molecular surveillance, and prudent antimicrobial stewardship to stop the spread of high-risk K. pneumoniae strains in healthcare environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.